– SAN DIEGO (GLOBE NEWSWIRE) - Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…
– WALTHAM, MA (BUSINESS WIRE)— BG Medicine, Inc., a U.S.-based life sciences company, announced today that the U.S. Food and Drug Administration has cleared the company’s Galectin-3 test for use in conjunction with clinical evaluation as an aid to assess the prognosis of patients diagnosed…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients. The study showed that APD515…
– SAN DIEGO (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced initiation of active patient recruitment in a Phase 2b clinical trial of emricasan in patients…
– SAN DIEGO - Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced initiation of dosing in the Phase 2 clinical trial of emricasan in patients with severe alcoholic…
– Cambridge, UK – Acacia Pharma, the pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million ($23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond…
– Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence IRVINE, CA and AMSTERDAM, THE NETHERLANDS - Agendia, a leader in molecular cancer diagnostics, announced today that researchers have identified a subset of breast cancer patients whose standard…
– HAYWARD, California - Moximed®, Inc. announced today that enrollment has been completed in its US-based SOAR clinical study. Patients enrolled in the SOAR clinical study were treated with the KineSpring® System, an implantable medical spring that works by unloading weight in the knee…
– Utrecht (the Netherlands) / Cambridge (USA) — Gilde Healthcare (‘Gilde’), the growth capital firm specialized in healthcare, announces it has sold its minority stake in biopharmaceutical company ProFibrix (Leiden, the Netherlands) to US listed pharmaceutical company The Medicines…
– SAN DIEGO -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biopharmaceutical company focused on the development and commercialization of novel medicines to treat liver disease, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a…
– Hørsholm, Denmark/San Diego, California & Cambridge, Massachusetts — Santaris Pharma A/S and RaNA Therapeutics, Inc. announced that they have signed an agreement whereby RaNA gains access to Santaris’ Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines. Under the…
– Amsterdam, the Netherlands — uniQure B.V. announced it has signed collaboration agreements with Chiesi Farmaceutici SpA for the commercialization of Glybera, the first gene therapy to receive regulatory approval in Europe, as well as the co-development of a gene therapy for hemophilia…
– COPENHAGEN, Denmark – Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it has received a milestone payment from Merck KGaA, Darmstadt, Germany, related to the successful achievement of specific development objectives…
– San Diego, CA – Conatus Pharmaceuticals Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the…
– Leiden, the Netherlands, Parsippany, NJ and Seattle, WA - The Medicines Company (NASDAQ: MDCO) and ProFibrix B.V. today announced an agreement for The Medicines Company to purchase all of the outstanding capital stock of ProFibrix B.V. subject to The Medicines Company’s satisfactory…
– Veteran Diagnostics and Biotech Executive to Lead Global Commercialization IRVINE, CA, and AMSTERDAM, THE NETHERLANDS - Agendia, a leader in molecular cancer diagnostics, today announced the addition of Peter W. Schineller as its Chief Commercial Officer. In this newly created position,…
– ASCO Presentation and Poster on Sym004 in mCRC and SCCCHN Copenhagen, Denmark – Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today at the 2013 Annual Meeting of the American Society of Clinical Oncology ( ASCO) the results…
– Utrecht, the Netherlands and Boston, USA – Gilde Healthcare, an investment firm focused on private healthcare companies, today announced that Bob Silverman has been appointed as Operational Partner. His main focus will be on supporting Gilde’s investments in diagnostics and medical…
– Copenhagen, Denmark – Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it closed an expansion of its previously announced €100 million financing attaining a total of a €141 million placement of preferred stock to a…
– Revenues Continue to Ramp in 2013 IRVINE, CA – Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone. The MammaPrint test analyzes 70 key genes…
– Freising, Germany – Pieris AG has achieved the second milestone for the first of two programs in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment,…
– Hørsholm, Denmark / San Diego, California — Santaris Pharma A/S, a privately held biopharmaceutical company announced a worldwide strategic alliance with Bristol-Myers Squibb (NYSE: BMY) to develop novel medicines using Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug…
– COPENHAGEN, Denmark - Symphogen today at the Annual Meeting of the American Association for Cancer Research in Washington DC, presented new preclinical data suggesting that a mixture of antibodies, known as pan-HER, that simultaneously inhibits EGFR, HER2 and HER3, is superior to…
– Deal Expanded to Include Additional Multispecific Anticalins Freising, Germany – Pieris AG and The Sanofi Group have jointly agreed to expand their ongoing discovery and development partnership to include a novel multispecific Anticalin program. Under the existing framework of the…
– Company remains on track for 2013 filings in US and Europe LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in innovative bioactive products to stop bleeding (hemostasis), today announced that the company has completed enrolment of its pivotal Phase III clinical trial…
– The First MicroRNA-Targeted Drug to Enter Clinical Trials Hørsholm, Denmark/San Diego, California — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the publication of study results…
– Munich, Germany – Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, today announced it has appointed an Advisory Board comprising renowned industry experts and visionaries in digital pathology. As part of its market expansion strategy,…
– CAMBRIDGE, MA, Amsterdam, the Netherlands — uniQure has been identified in the field of biomedicine as one of 2013’s 50 Disruptive Companies, MIT Technology Review’s annual list of the world’s most innovative technology companies. The honorees are nominated by MIT Technology Review’s…
– REGULATED INFORMATION GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], the biopharmaceutical company focused on the discovery and development of Nanobodies®, announces today that it has raised €31.5 million through a private placement of new shares via an accelerated bookbuilding…
– Munich, Germany – Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, announced the appointment of renowned surgical and anatomical pathologist Dr. Ralf Huss as Chief Medical Officer (CMO). Professor Huss brings significant expertise…
– GHENT, Belgium and LONDON, United Kingdom, 25 February 2013 - Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines…
– ACR20, ACR50 and ACR70 scores of up to 100%, 75% and 63% respectively Up to 75% of patients in DAS28 remission Attractive safety profile at all administered doses No anti-drug antibodies detected No disease progression as determined by MRI radiography GHENT, Belgium - Ablynx…
– MammaPrint Test Accurately Predicts Breast Cancer Recurrence; In First Prospective, Outcome-Based Study of Its Kind IRVINE, CA and AMSTERDAM, THE NETHERLANDS – The MammaPrint breast cancer test can dramatically reduce the number of women who need to undergo chemotherapy to treat…
– Oxford – Chroma Therapeutics Limited announced today that GlaxoSmithKline (GSK) has approved the progression of Chroma’s novel macrophage-targeted HDAC inhibitor, CHR-5154, towards human clinical development subject to regulatory approval, triggering an undisclosed milestone payment…